2020 Best of Breast

The Best of Breast is a new and innovative conference on breast cancer set completely in a multidisciplinary tumor board environment. The world’s leading breast cancer experts will discuss cases beginning with high risk characteristics and take us through to survivorship all the while incorporating data from the major oncologic annual meetings. Expert panelists include breast surgeons, plastic surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, geneticists, psychologists, pharmacists, advanced practitioners, and nurses. 

Get Started Now

Enroll in Course

Learning Objectives

Analyze new strategies in screening and prevention, especially in at-risk populations

Define the optimal patient demographic for the array of genomic assays, including the definitions of prognostic value, predictive value, and negative predictive value

Distinguish the role of the AJCC staging guidelines in practice

Accreditation Information

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 10.75 AMA PRA Category 1 CreditsTM for physicians and 10.75 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.  

 

How This Course Works

This course consists of pre-recorded sessions that took place at the 2020 Best of Breast Conference on January 18-19, 2020.

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

A link to the evaluation will be provided at the conclusion of the course.

If you have questions regarding this enduring material activity, please contact us at certificates@amedcoemail.com.

 

Frequently Asked Questions

How do I access my CME/CE Credits?

A link will be provided you to you at the conclusion of the course. You will be asked to fill out a brief evaluation and your certificate will be automatically emailed back to you.

How long do I have access to the course?

The course will be available to access until April 16, 2023. 

Can I have face to face interaction with Instructor?

No, this is an online self-paced course with video demonstration. However, you are free to connect with the medical experts for each session on social media or contact the team and we will connect you.

How many credits can I obtain?

Amedco LLC designates this enduring activity for a maximum of 10.75 AMA PRA Category 1 CreditsTM for physicians and 10.75 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.  

Course Curriculum

  • 2020 Best of Breast Learners Notification
    5 minutes
  • Case of 54 y/o F With Metastatic Breast Cancer: Eligibility for Genetic Testing & Data on Olaparib and Talazoparib for Pts With Germline BRCA Mutations
    20 minutes
  • Case of 54 y/o F With Metastatic Breast Cancer: Altering Treatment Plan Bc the Somatic and Germline Testing Was Not Concordant? & Why Is Important to Know Both the Germline and Somatic Results?
    12 minutes
  • Case of 53 y/o Post-menopausal F With TNBC Who Undergoes Genetic Testing: RAD51 Mutation, Incorporating Platinum in the Neoadjuvant Setting & PARPi in the Metastatic and Curative Setting
    24 minutes
  • Case of 53 y/o Post-menopausal F With TNBC and Mutations in RAD51: Cascade Testing & Recommended Management of BRCA 1/2 Mutation
    20 minutes
  • Treatment of 45 y/o With CHEK2 Mutated Breast Cancer: Screening Guidelines for High Risk Pts
    21 minutes
  • Decision Making in Early Stage BC – Case of 36 y/o Pre-Menopausal Woman: Is There a Role for Breast MRI? Considering Neoadjuvant Therapy? Using Genomic Test to Determine Benefit of Chemo?
    14 minutes
  • Decision Making in Early Stage Breast Cancer – Case of 36 y/o Pre-Menopausal Woman: Using Anthracycline Chemo? Data from ABC Trials – The TaxAC Regimens Improved IDFS
    13 minutes
  • Decision Making in Early Stage Breast Cancer – Case of 36 y/o Pre-Menopausal Woman: Scalp Cooling Benefits, Post-Mastectomy Radiation, Which Adjuvant Hormonal Therapy Is Recommended, Long Term Adherence to AET, Fertility Preservation
    30 minutes
  • Decision Making in Early Stage Breast Cancer – Late Recurrence and Genomic Assay Data: Trials of TAM + Al and Extended Al & BCI Predicts Benefit from Extended Tamoxifen
    16 minutes
  • Combating Endocrine Resistance in Breast Cancer: Side Effects Management & Suppression of Ovarian Function With Tamoxifen Significantly Improves DFS
    11 minutes
  • Treatment of 52 y/o Post-Menopausal Woman HER2- Breast Cancer & Bone Mets: Clinical Significance of Loco-Regional Recurrence & Data on Stereotactic Ablative Radiotherapy
    13 minutes
  • Discussion on Systemic Treatment Algorithm for HR+, HER2- Recurrent Breast Cancer: Review of Approved CDK4/6 Inhibitors and Related Trials, Differences in Dosing and Safety & Managing Side Effects
    16 minutes
  • Treatment of Post-Menopausal Woman in the 2nd Line Setting After Progression on CDK4/6 and AI: Data on Alpelisib + Fulvestrant and Other Treatment Options & PARP Inhibitors for gBRCA Mutated BC
    14 minutes
  • Treatment of 57 y/o Post-Menopausal Woman With HER2+ Breast Cancer: Repeating HER2 Testing on Surgical Specimen & Data on HER2 ISH Testing Using a Dual-Probe Assay
    14 minutes
  • Treatment of 57 y/o Post-Menopausal Woman With HER2+ Breast Cancer – Options for Early Stage Disease: Discussing Data on Paclitaxel/Trastuzumab, T-DM1, & Pertuzumab and Trastuzumab
    15 minutes
  • Treatment of 57 y/o Post-Menopausal Woman With HER2+ Breast Cancer: Consulting Cardiologist for Asymptomatic Drops in EF During Adjuvant Trastuzumab, Radiation Considerations to Optimize Therapy & Taxane-Induced Neuropathy
    18 minutes
  • Treatment of 57 y/o Post-Menopausal Woman With HER2+ Breast Cancer and Developed Brain Mets: Gamma Knife for Brain Lesions, 2nd Line Therapy With Neratinib + Xeloda & New Data on Tucatinib Show Significant Progress
    10 minutes
  • Treatment of 57 y/o Post-Menopausal Woman with HER2+ Breast Cancer and Progression in Liver – Data on Durable Efficacy of Trastuzumab Deruxtecan
    10 minutes
  • Treatment Options for 55 y/o Woman With T2, Node Negative TNBC: Neoadjuvant Chemo First? Platinum or Checkpoint Inhibition + Chemo? Reviewing Data From IO Trials
    34 minutes
  • Treatment of 55 y/o Woman with T2, Node Negative TNBC: Checking Residual Cancer Burden Score? Considering Adjuvant Capecitabine?
    13 minutes
  • Treatment of 55 y/o Woman with T2, Node Negative TNBC – Developing Adrenal Insufficiency After Nab-Paclitaxel + Atezolizumab, Management of Endocrinopathies & New Agents in TNBC
    14 minutes
  • Cardiac Oncology: Management of Cardiovascular Toxicity, Tools for the Detection and Strategies to Reduce Toxicity
    26 minutes
  • Case of 62 y/o Woman With Metastatic Breast Cancer Treated With Alpelisib + Fulvestrant: Management of Hyperglycemia (Metformin, GLP-1 Agonists and DPP-4)
    20 minutes
  • Case of 65 y/o Woman With Breast Cancer Treated With Pembro: Management of Hypothyroidism Developed After Checkpoint Inhibitor Treatment
    11 minutes
  • Breast Cancer and Impact of Low Access to Innovative and Essential Medicines & High Cost Medications
    21 minutes
  • Cost of Developing New Drugs, Access to Innovative Cancer Drugs, & Improving Cost Effectiveness with Generics and Biosimilars
    15 minutes
  • Cost Considerations and the Future Direction of Breast Cancer
    20 minutes

Get Started Now

Enroll in Course